The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.


TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.

Research Programme

The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.  


If you have any questions you can fill in the form or mail us directly:


King's College publishes on RNAemia and proteome biomarker risk stratification in intensive care unit patients with COVID-19

Circulating SARS-CoV-2 RNA (RNAemia) has been highlighted as a promising prognostic biomarker in hospitalized COVID-19 patients, as it is associated with disease severity and mortality, with an estimated prevalence of 10%. Further, they hypothesized that the acute and profound alterations in the innate and adaptive immune system in COVID-19 patients, especially in RNAemic patients, will be accompanied by marked changes in the circulating proteome and interactome and that the proteome in COVID-19 patients will highlight mechanistically relevant signatures and trajectories, when compared to non-COVID-19 sepsis and healthy controls. Thus far, proteomics studies have focused on the determination of protein biomarkers of COVID-19 severity, but have not assessed the longitudinal relationship between proteomic changes, RNAemia and 28-day mortality. In this paper, the group of Prof. Mayr at King’s College London assessed RNAemia, antibody response against SARS-CoV-2 and proteomic profiles in serial blood samples from COVID-19 patients admitted to two ICUs.

Their preprint, "SARS-CoV-2 RNAemia and proteomic biomarker trajectory inform prognostication in COVID-19 patients admitted to intensive care," has been posted to Research Square. It has been assigned a DOI and is now a permanent and citable part of the scholarly record. The DOI is: 10.21203/

Link below: